MARKET

FSTX

FSTX

F-star Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.724
+0.064
+1.75%
Opening 09:45 01/27 EST
OPEN
3.710
PREV CLOSE
3.660
HIGH
3.724
LOW
3.680
VOLUME
4.01K
TURNOVER
--
52 WEEK HIGH
15.50
52 WEEK LOW
3.510
MARKET CAP
76.81M
P/E (TTM)
-0.5430
1D
5D
1M
3M
1Y
5Y
F-star Therapeutics gets US patent for antibody FS118
F-star Therapeutics (FSTX +3.7%) said the U.S. Patent and Trademark Office granted a patent protecting the composition of matter of the company's tetravalent bispecific antibody FS118, which blocks PD-L1 and LAG-3
Seekingalpha · 6d ago
F-star Announces Issuance Of US Patent Protecting FS118, A Bispecific Antibody Targeting PD-L1 And LAG-3
Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star
Benzinga · 01/20 13:14
BRIEF-F-Star Announces Issuance Of U.S. Patent Protecting Fs118, A Bispecific Antibody Targeting Pd-L1 And Lag-3
reuters.com · 01/20 13:10
F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-s...
GlobeNewswire · 01/20 13:00
F-star Therapeutics Secures US Patent for FS118 Bispecific Antibody
MT Newswires · 01/20 09:39
BRIEF-F-Star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises A Fourth Licensing Option In Immuno-Oncology Collaboration
reuters.com · 01/05 13:07
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives...
GlobeNewswire · 01/05 13:00
Peering Into F-star Therapeutics Recent Short Interest
F-star Therapeutics Inc. - Common Stock's (NASDAQ:FSTX) short percent of float has fallen 90.16% since last its last report. The company recently reported that it has 108.00 thousand shares sold short, which is 0.67% of all regular shares that are availabl...
Benzinga · 12/31/2021 18:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FSTX. Analyze the recent business situations of F-star Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FSTX stock price target is 29.67 with a high estimate of 35.00 and a low estimate of 15.00.
High35.00
Average29.67
Low15.00
Current 3.724
EPS
Actual
Estimate
-1.68-1.26-0.84-0.42
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 70
Institutional Holdings: 12.18M
% Owned: 59.04%
Shares Outstanding: 20.62M
TypeInstitutionsShares
Increased
12
175.63K
New
4
16.42K
Decreased
11
674.34K
Sold Out
8
605.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.98%
Pharmaceuticals & Medical Research
+1.59%
Key Executives
Non-Executive Chairman/Independent Director
Nessan Bermingham
President/Chief Executive Officer/Director
Eliot Forster
Chief Financial Officer/Treasurer
Darlene Deptula-Hicks
Chief Scientific Officer
Neil Brewis
Other
Louis Kayitalire
Independent Director
David Arkowitz
Independent Director
Edward Benz
Independent Director
Todd Brady
Independent Director
Pamela Klein
Independent Director
Patrick Johan Hendrik Krol
Independent Director
Geoffrey Race
No Data
  • All
  • Financials
  • Insiders
More
About FSTX
F-Star Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS120, FS222 and SB 11285 in Phase 1 clinical trials in patients with advanced cancers. FS120 is a bispecific natural antibody that binds to OX40 and CD137. FS120 is a dual costimulatory antibody or agonist that hits the gas on immune activation by activating both CD137 and OX40. FS222 is developed to target costimulatory CD137 and the inhibitory PD-L1 receptors, which are tumor types including non-small-cell lung cancer, ovarian cancer and gastrointestinal cancers such as colorectal and esophageal cancer. SB 11285 is an immunotherapeutic synthetic cyclic dinucleotide for the treatment of selected cancers.

Webull offers kinds of F-Star Therapeutics Inc stock information, including NASDAQ:FSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FSTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FSTX stock methods without spending real money on the virtual paper trading platform.